225 related articles for article (PubMed ID: 8540697)
1. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.
van Etten EW; ten Kate MT; Stearne LE; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 1995 Sep; 39(9):1954-8. PubMed ID: 8540697
[TBL] [Abstract][Full Text] [Related]
2. Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice.
van Etten EW; Snijders SV; van Vianen W; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 1998 Sep; 42(9):2431-3. PubMed ID: 9736577
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.
Van Etten EW; Stearne-Cullen LE; ten Kate M; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2000 Mar; 44(3):540-5. PubMed ID: 10681315
[TBL] [Abstract][Full Text] [Related]
4. Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome and fungizone against intracellular Candida albicans in murine peritoneal macrophages.
van Etten EW; van Vianen W; Hak J; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 1998 Sep; 42(9):2437-9. PubMed ID: 9736579
[TBL] [Abstract][Full Text] [Related]
5. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.
van Etten EW; van den Heuvel-de Groot C; Bakker-Woudenberg IA
J Antimicrob Chemother; 1993 Nov; 32(5):723-39. PubMed ID: 8125837
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans.
van Etten EW; Otte-Lambillion M; van Vianen W; ten Kate MT; Bakker-Woudenberg AJ
J Antimicrob Chemother; 1995 Apr; 35(4):509-19. PubMed ID: 7628985
[TBL] [Abstract][Full Text] [Related]
7. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans.
van Etten EW; Chander HR; Snijders SV; Bakker-Woudenberg IA
J Antimicrob Chemother; 1995 Dec; 36(6):961-74. PubMed ID: 8821595
[TBL] [Abstract][Full Text] [Related]
8. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
Kretschmar M; Nichterlein T; Hannak D; Hof H
Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis.
Wasan KM; Conklin JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1806-10. PubMed ID: 8843285
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.
Gondal JA; Swartz RP; Rahman A
Antimicrob Agents Chemother; 1989 Sep; 33(9):1544-8. PubMed ID: 2684010
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
12. Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice.
van Etten EW; van Vianen W; Roovers P; Frederik P
Antimicrob Agents Chemother; 2000 Jun; 44(6):1598-603. PubMed ID: 10817715
[TBL] [Abstract][Full Text] [Related]
13. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.
Otsubo T; Maruyama K; Maesaki S; Miyazaki Y; Tanaka E; Takizawa T; Moribe K; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 1998 Jan; 42(1):40-4. PubMed ID: 9449258
[TBL] [Abstract][Full Text] [Related]
14. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis.
Pahls S; Schaffner A
J Infect Dis; 1994 May; 169(5):1057-61. PubMed ID: 8169391
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
17. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
19. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.
Mohamed HA; Radwan RR; Raafat AI; Ali AE
Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Andes D; Safdar N; Marchillo K; Conklin R
Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
